Literature DB >> 1320366

In vitro activities of five quinolones against Chlamydia pneumoniae.

M R Hammerschlag1, C L Hyman, P M Roblin.   

Abstract

The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae were determined for five quinolones, including ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, and sparfloxacin. Sparfloxacin was the most active compound tested, followed by ofloxacin and temafloxacin. Ciprofloxacin and fleroxacin were the least active. The use of HEp-2 cells for testing C. pneumoniae resulted in larger inclusions but essentially the same endpoints as were seen with use of HeLa 229 cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320366      PMCID: PMC190581          DOI: 10.1128/AAC.36.3.682

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Authors:  K Chirgwin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

Review 3.  Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies.

Authors:  J M Ehret; F N Judson
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 4.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

5.  In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.

Authors:  J Segreti; D J Hirsch; A A Harris; K S Kapell; H Orbach; H A Kessler
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Infection with Chlamydia pneumoniae in Brooklyn.

Authors:  K Chirgwin; P M Roblin; M Gelling; M R Hammerschlag; J Schachter
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

7.  Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors:  B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

Review 8.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

  8 in total
  23 in total

Review 1.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; A Kutlin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 5.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  In vitro and in vivo activities of sitafloxacin against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors:  M Kimura; T Kishimoto; Y Niki; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.

Authors:  M Trautmann; M Ruhnke; K Borner; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope.

Authors:  M Perez Melgosa; C C Kuo; L A Campbell
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.